Biochemical and biophysical assessment of MTX‐induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan<sup>®</sup> predicts the absence of significant liver fibrosis

Berends, M.A.M.; Snoek, Josje; Jong, E.M.G.J. de; Krieken, J. Han van; Knegt, Robert J. de; Oijen, Martijn G.H. van; Kerkhof, Peter C M van de; Drenth, Joost P.H.

doi:10.1111/j.1478-3231.2007.01489.x

Cited by 75 publications

(82 citation statements)

References 32 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a study performed in the Netherlands [15] , using a cutoff value of 7.1 kPa, 88% of the patients who did not have significant fibrosis (F < 2 Metavir) were correctly identified.…”

Section: Discussionmentioning

confidence: 99%

“…All studies show that, by using a cut-off value of 6.8-7.5 kPa, we could identify accurately enough the patients who need to be treated (F ≥ 2 Metavir) vs those who should not be treated (F < 2 Metavir), and this without performing a LB [13][14][15] . The PPV of 98% obtained in our study for a cut-off value of 6.8 kPa suggests that we can quite accurately identify patients who must be treated (F ≥ 2 Metavir).…”

Section: Discussionmentioning

confidence: 99%

“…Ziol et al [12] 494 7.5 Foucher et al [13] 354 7.2 Kim et al [14] 47 7.3 Berends et al [15] 24 7.1 Lupşor et al [16] 324 7.4 Present study 199 6.8 Table 1 Cut-off values for significant fibrosis (at least F2 Metavir) in various studies…”

Section: Studymentioning

confidence: 99%

See 2 more Smart Citations

Comparison of the liver stiffness measurement by transient elastography with the liver biopsy

Sporea¹,

Şirli²,

Deleanu³

et al. 2008

WJG

View full text Add to dashboard Cite

AIM:To compare the liver stiffness (LS) measurement by transient elastography (TE) to the liver biopsy (LB)-considered the "gold standard" in the evaluation of patients with chronic hepatitis C. METHODS: During a period of 12 mo, we evaluated 199 consecutive patients with chronic hepatitis due to hepatitis C virus (HCV), in which LB and LS assessments (by means of TE) were performed during the same session. RESULTS: Out of 199 patients, a valid measurement of the LS could not be obtained in 8. The mean value of LS in the cohort of 191 valid measurements was 8.45 ± 4.96 kPa, ranging from 2.3 to 38 kPa. The mean value of LS in patients with significant fibrosis at biopsy (161 patients with F ≥ 2 according to Metavir) was 9.02 ± 5.15 kPa, significantly higher than in patients with no or mild fibrosis (30 patients with F < 2 Metavir): 5.39 ± 1.81 kPa (P < 0.0001). For a cutoff value of 6.8 kPa, the LS had a PPV of 98%, a NPV of 30.1%, a sensitivity of 59.6% and a specificity of 93.3% for the presence of significant fibrosis (at least F2 Metavir), with a diagnostic performance of 77.3% (AUROC 0.773). Using this cut-off value, we reached the best discrimination between absence of fibrosis/ mild fibrosis (F < 2 Metavir) and the presence of moderate to severe fibrosis (F ≥ 2 Metavir). CONCLUSION: In patients with chronic hepatitis due to HCV, a cut-off value of 6.8 kPa measured by TE can differentiate between significant fibrosis and absent or mild fibrosis, with a PPV of 98%, a NPV of 30.1%, a sensitivity of 59.6%, a specificity of 93.3%, and a diagnostic performance of 77.3%.

show abstract

“…In a study performed in the Netherlands [15] , using a cutoff value of 7.1 kPa, 88% of the patients who did not have significant fibrosis (F < 2 Metavir) were correctly identified.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the liver stiffness measurement by transient elastography with the liver biopsy

Sporea¹,

Şirli²,

Deleanu³

et al. 2008

WJG

View full text Add to dashboard Cite

show abstract

“…Thus, the use of MTX in psoriatic patients should be carefully monitored for the possible worsening of a pre-existing steatohepatitis [24] . Thus, in MTX users, FibroTest can accurately predict the presence of liver fibrosis and the Fibroscan significantly predict the absence of significant liver fibrosis [106] . CsA is a potent immunosuppressor used for organ transplantations and various autoimmune disorders; one of the most detectable side effects is hepatotoxicity [107] .…”

Section: Conventional Psoriatic Treatments and Liver Function Implicamentioning

confidence: 99%

Non-alcoholic fatty liver disease and psoriasis: So far, so near

Ganzetti

Campanati

Offidani

2015

WJH

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory immune-mediated skin diseases which is frequently associated to comorbidities. Non-alcoholic fatty liver disease (NAFLD) is defined as an excessive accumulation of triglycerides in hepatocytes and includes a wide spectrum of liver conditions ranging from relatively benign steatosis to non-alcoholic steatohepatitis with fatty infiltration and lobular inflammation and to cirrhosis and endstage liver disease. Actually, psoriasis is considered a systemic diseases associated to comorbidities, as metabolic syndrome and NAFLD is seen the hepatic manifestation of the metabolic syndrome. The possible link between psoriasis, obesity and metabolic syndrome, which are known risk factors for NAFLD has been recently documented focusing in the crucial role of the adipose tissue in the development of the inflammatory background sharing by the above entities. According to recent data, patients with psoriasis show a greater prevalence of NAFLD and metabolic syndrome than the general population. Moreover, patients with NAFLD and psoriasis are at higher risk of severe liver fibrosis than those with NAFLD and without psoriasis. The link between these pathological conditions appears to be a chronic low-grade inflammatory status. The aim of this review is to focus on the multiple aspects linking NAFLD and psoriasis, only apparently far diseases. Core tip: The review focuses on the multiple physiopathogenetic aspects of the possible link between psoriasis and non-alcoholic fatty liver disease (NAFLD) emphasizing the most recent scientific data. The importance of the multidisciplinary approach to patients affected by psoriasis is underlined and the therapeutic options to treat concomitant psoriasis and NAFLD is discussed evaluating the risk benefit of both biologic and non-biologic therapies.Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol 2015; 7(3): 315-326 Available from:

show abstract

“…Vergniol et al (Vergniol et al 2009) suggested that Fibroscan(r) should be useful for assessing treatment efficacy in clinical trials of new drugs. Recently, Berends et al (Berends et al 2007) reported that Fibroscan(r) accurately predicted the absence of significant liver fibrosis in methotrexate users.…”

Section: Treatment Follow-upmentioning

confidence: 99%

Non-Invasive Assessment of Liver Fibrosis by Vibration-Controlled Transient Elastography (Fibroscan®)

Sandrin¹,

Oudry²,

Bastard³

et al. 2011

Liver Biopsy

View full text Add to dashboard Cite

Biochemical and biophysical assessment of MTX‐induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan^® predicts the absence of significant liver fibrosis

Cited by 75 publications

References 32 publications

Comparison of the liver stiffness measurement by transient elastography with the liver biopsy

Comparison of the liver stiffness measurement by transient elastography with the liver biopsy

Non-alcoholic fatty liver disease and psoriasis: So far, so near

Non-Invasive Assessment of Liver Fibrosis by Vibration-Controlled Transient Elastography (Fibroscan®)

Contact Info

Product

Resources

About

Biochemical and biophysical assessment of MTX‐induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan® predicts the absence of significant liver fibrosis

Cited by 75 publications

References 32 publications

Comparison of the liver stiffness measurement by transient elastography with the liver biopsy

Comparison of the liver stiffness measurement by transient elastography with the liver biopsy

Non-alcoholic fatty liver disease and psoriasis: So far, so near

Non-Invasive Assessment of Liver Fibrosis by Vibration-Controlled Transient Elastography (Fibroscan®)

Contact Info

Product

Resources

About

Biochemical and biophysical assessment of MTX‐induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan^® predicts the absence of significant liver fibrosis